JP2019533675A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019533675A5 JP2019533675A5 JP2019520024A JP2019520024A JP2019533675A5 JP 2019533675 A5 JP2019533675 A5 JP 2019533675A5 JP 2019520024 A JP2019520024 A JP 2019520024A JP 2019520024 A JP2019520024 A JP 2019520024A JP 2019533675 A5 JP2019533675 A5 JP 2019533675A5
- Authority
- JP
- Japan
- Prior art keywords
- domain
- antibody molecule
- tetravalent antibody
- amino acid
- acid sequence
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2023069848A JP2023093642A (ja) | 2016-10-14 | 2023-04-21 | モジュラー四価二重特異性抗体プラットフォーム |
| JP2025119440A JP2025142045A (ja) | 2016-10-14 | 2025-07-16 | モジュラー四価二重特異性抗体プラットフォーム |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662408271P | 2016-10-14 | 2016-10-14 | |
| US62/408,271 | 2016-10-14 | ||
| PCT/US2017/056814 WO2018071913A2 (en) | 2016-10-14 | 2017-10-16 | Modular tetrameric bispecific antibody platform |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023069848A Division JP2023093642A (ja) | 2016-10-14 | 2023-04-21 | モジュラー四価二重特異性抗体プラットフォーム |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2019533675A JP2019533675A (ja) | 2019-11-21 |
| JP2019533675A5 true JP2019533675A5 (enExample) | 2020-11-26 |
| JP7269167B2 JP7269167B2 (ja) | 2023-05-08 |
Family
ID=60327374
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019520024A Active JP7269167B2 (ja) | 2016-10-14 | 2017-10-16 | モジュラー四価二重特異性抗体プラットフォーム |
| JP2023069848A Pending JP2023093642A (ja) | 2016-10-14 | 2023-04-21 | モジュラー四価二重特異性抗体プラットフォーム |
| JP2025119440A Pending JP2025142045A (ja) | 2016-10-14 | 2025-07-16 | モジュラー四価二重特異性抗体プラットフォーム |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023069848A Pending JP2023093642A (ja) | 2016-10-14 | 2023-04-21 | モジュラー四価二重特異性抗体プラットフォーム |
| JP2025119440A Pending JP2025142045A (ja) | 2016-10-14 | 2025-07-16 | モジュラー四価二重特異性抗体プラットフォーム |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US20200017588A1 (enExample) |
| EP (1) | EP3526257A2 (enExample) |
| JP (3) | JP7269167B2 (enExample) |
| CN (2) | CN120795163A (enExample) |
| AU (2) | AU2017341936B2 (enExample) |
| CA (1) | CA3038504A1 (enExample) |
| WO (1) | WO2018071913A2 (enExample) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SG11201900500TA (en) * | 2016-07-22 | 2019-02-27 | Dana Farber Cancer Inst Inc | Glucocorticoid-induced tumor necrosis factor receptor (gitr) antibodies and methods of use thereof |
| JP7231549B2 (ja) * | 2017-02-06 | 2023-03-01 | デイナ ファーバー キャンサー インスティチュート，インコーポレイテッド | 抗体媒介性受容体シグナル伝達を増強するための組成物及び方法 |
| WO2020102233A1 (en) * | 2018-11-13 | 2020-05-22 | Jn Biosciences Llc | Bispecific antibodies for activation of immune cells |
| JP2022510218A (ja) * | 2018-11-30 | 2022-01-26 | メモリアル スローン ケタリング キャンサー センター | ヘテロ二量体四価特異性抗体およびこれらの使用 |
| WO2021113307A2 (en) * | 2019-12-02 | 2021-06-10 | Dana-Farber Cancer Institute, Inc. | Antibodies against pd-l1 and methods of use thereof |
| CN113563473A (zh) * | 2020-04-29 | 2021-10-29 | 三生国健药业（上海）股份有限公司 | 四价双特异性抗体、其制备方法和用途 |
| WO2021226984A1 (zh) * | 2020-05-15 | 2021-11-18 | 三生国健药业（上海）股份有限公司 | 一种抗pd-1和pd-l1的四价双特异性抗体 |
| WO2022182891A1 (en) | 2021-02-25 | 2022-09-01 | Lyell Immunopharma, Inc. | Ror1 targeting chimeric antigen receptor |
| WO2023034288A1 (en) | 2021-08-31 | 2023-03-09 | Dana-Farber Cancer Institute, Inc. | Compositions and methods for treatment of autoimmune disorders and cancer |
| EP4436998A1 (en) | 2021-11-24 | 2024-10-02 | Dana-Farber Cancer Institute, Inc. | Antibodies against ctla-4 and methods of use thereof |
| US20250255902A1 (en) | 2022-03-09 | 2025-08-14 | Dana-Farber Cancer Institute, Inc. | Genetically engineered b cells and methods of use thereof |
| CA3263672A1 (en) | 2022-08-15 | 2024-02-22 | Dana-Farber Cancer Institute, Inc. | ANTI-MLSN ANTIBODIES AND THEIR METHODS OF USE |
| KR20250099103A (ko) | 2022-08-15 | 2025-07-01 | 다나-파버 캔서 인스티튜트 인크. | Cldn4에 대한 항체 및 이의 사용 방법 |
| AU2024313549A1 (en) * | 2023-06-20 | 2025-10-30 | Denali Therapeutics Inc. | Dual transporters and methods of use |
Family Cites Families (37)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5892019A (en) | 1987-07-15 | 1999-04-06 | The United States Of America, As Represented By The Department Of Health And Human Services | Production of a single-gene-encoded immunoglobulin |
| DE4118120A1 (de) * | 1991-06-03 | 1992-12-10 | Behringwerke Ag | Tetravalente bispezifische rezeptoren, ihre herstellung und verwendung |
| EP1411983A4 (en) * | 2001-06-26 | 2006-06-21 | Imclone Systems Inc | BISPECIFIC ANTIBODIES BINDING TO VEGF RECEPTORS |
| WO2005047327A2 (en) | 2003-11-12 | 2005-05-26 | Biogen Idec Ma Inc. | NEONATAL Fc RECEPTOR (FcRn)-BINDING POLYPEPTIDE VARIANTS, DIMERIC Fc BINDING PROTEINS AND METHODS RELATED THERETO |
| CN1914226B (zh) | 2003-11-25 | 2012-02-01 | 达纳-法伯癌症研究院有限公司 | SARS-CoV抗体及其使用方法 |
| WO2005054868A1 (en) * | 2003-12-05 | 2005-06-16 | Multimmune Gmbh | Compositions and methods for the treatment and diagnosis of neoplastic and infectious diseases |
| WO2006074399A2 (en) * | 2005-01-05 | 2006-07-13 | Biogen Idec Ma Inc. | Multispecific binding molecules comprising connecting peptides |
| CA2597717C (en) | 2005-02-18 | 2014-10-21 | Dana-Farber Cancer Institute | Antibodies against cxcr4 and methods of use thereof |
| EP1979379B1 (en) | 2005-12-02 | 2013-09-18 | Dana-Farber Cancer Institute | Carbonic anhydrase ix (g250) antibodies and methods of use thereof |
| WO2009079259A2 (en) | 2007-12-06 | 2009-06-25 | Dana-Farber Cancer Institute, Inc. | Antibodies against influenza virus and methods of use thereof |
| US8962806B2 (en) | 2007-12-28 | 2015-02-24 | Dana-Farber Cancer Institute, Inc. | Humanized monoclonal antibodies and methods of use |
| WO2009148640A2 (en) * | 2008-02-22 | 2009-12-10 | Dow Global Technologies Inc. | Thermal energy storage materials |
| NZ600820A (en) | 2009-12-29 | 2014-12-24 | Emergent Product Dev Seattle | Heterodimer binding proteins and uses thereof |
| EP3957653A1 (en) | 2010-06-02 | 2022-02-23 | Dana Farber Cancer Institute, Inc. | Humanized monoclonal antibodies and methods of use |
| EP2543680A1 (en) * | 2011-07-07 | 2013-01-09 | Centre National de la Recherche Scientifique | Multispecific mutated antibody Fab fragments |
| CA2854806A1 (en) * | 2011-11-07 | 2013-05-16 | Medimmune, Llc | Multispecific and multivalent binding proteins and uses thereof |
| BR112014015018A2 (pt) * | 2011-12-19 | 2020-10-27 | Synimmune Gmbh | moléculas de anticorpo biespecífico e seu método de produção, bem como composição farmacêutica e molécula de ácido nucleico |
| CA2854246A1 (en) * | 2011-12-22 | 2013-06-27 | F. Hoffmann-La Roche Ag | Full length antibody display system for eukaryotic cells and its use |
| US8961971B2 (en) * | 2011-12-22 | 2015-02-24 | Development Center For Biotechnology | Bispecific T-cell activator antibody |
| EP2814846B1 (en) * | 2012-02-13 | 2020-01-08 | Seattle Children's Hospital d/b/a Seattle Children's Research Institute | Bispecific chimeric antigen receptors and therapeutic uses thereof |
| HK1207655A1 (en) | 2012-05-04 | 2016-02-05 | Dana-Farber Cancer Institute, Inc. | Affinity matured anti-ccr4 humanized monoclonal antibodies and methods of use |
| ES2924722T3 (es) * | 2012-05-18 | 2022-10-10 | Aptevo Res & Development Llc | Unión de inmunofusión de scFv biespecífico (BIf) a CD123 y CD3 |
| KR101947702B1 (ko) | 2012-10-04 | 2019-02-14 | 다나-파버 캔서 인스티튜트 인크. | 인간 단클론 항-pd-l1 항체 및 사용 방법 |
| CN105229029B (zh) * | 2012-11-19 | 2020-07-14 | 巴利奥医药股份公司 | 结合到cd20和cd95的重组双特异性抗体 |
| EP2968547B1 (en) * | 2013-03-15 | 2019-08-07 | Memorial Sloan Kettering Cancer Center | Multimerization technologies |
| EP2971042B1 (en) | 2013-03-15 | 2020-01-15 | Dana-Farber Cancer Institute, Inc. | Flavivirus neutralizing antibodies and methods of use thereof |
| HRP20240107T1 (hr) | 2013-05-20 | 2024-04-12 | F. Hoffmann - La Roche Ag | Protutijela na transferinski receptor i postupci uporabe |
| AR097306A1 (es) * | 2013-08-20 | 2016-03-02 | Merck Sharp & Dohme | Modulación de la inmunidad tumoral |
| RU2016129724A (ru) * | 2013-12-23 | 2018-01-30 | Займворкс Инк. | Антитела, содержащие с-концевые удлинения полипептида легкой цепи, их конъюгаты и способы применения |
| CA2940196C (en) | 2014-03-19 | 2023-03-07 | Wayne Marasco | Immunogenetic restriction on elicitation of antibodies |
| KR20160145813A (ko) | 2014-04-25 | 2016-12-20 | 다나-파버 캔서 인스티튜트 인크. | 중동 호흡기 증후군 코로나바이러스 중화 항체 및 이의 사용 방법 |
| PL3151921T3 (pl) * | 2014-06-06 | 2020-02-28 | Bristol-Myers Squibb Company | Przeciwciała przeciwko receptorowi indukowanego glukokortykoidami czynnika martwicy nowotworu (gitr) i ich zastosowania |
| WO2015197582A1 (en) | 2014-06-27 | 2015-12-30 | Innate Pharma | Monomeric multispecific antigen binding proteins |
| JP2017531427A (ja) | 2014-10-03 | 2017-10-26 | デイナ ファーバー キャンサー インスティチュート，インコーポレイテッド | グルココルチコイド誘導腫瘍壊死因子受容体（ｇｉｔｒ）抗体およびその使用法 |
| WO2016057488A1 (en) | 2014-10-06 | 2016-04-14 | Dana-Farber Cancer Institute, Inc. | Humanized cc chemokine receptor 4 (ccr4) antibodies and methods of use thereof |
| EP3280730B1 (en) | 2015-04-08 | 2024-01-03 | Dana-Farber Cancer Institute, Inc. | Humanized influenza monoclonal antibodies and methods of use thereof |
| US20220047634A1 (en) * | 2018-11-30 | 2022-02-17 | Dana-Farber Cancer Institute, Inc. | Chimeric antigen receptor factories and methods of use thereof |
-
2017
- 2017-10-16 EP EP17798026.5A patent/EP3526257A2/en active Pending
- 2017-10-16 CN CN202510732184.9A patent/CN120795163A/zh active Pending
- 2017-10-16 JP JP2019520024A patent/JP7269167B2/ja active Active
- 2017-10-16 CN CN201780067582.7A patent/CN110214152B/zh active Active
- 2017-10-16 WO PCT/US2017/056814 patent/WO2018071913A2/en not_active Ceased
- 2017-10-16 AU AU2017341936A patent/AU2017341936B2/en active Active
- 2017-10-16 US US16/340,878 patent/US20200017588A1/en not_active Abandoned
- 2017-10-16 CA CA3038504A patent/CA3038504A1/en active Pending
-
2023
- 2023-04-21 JP JP2023069848A patent/JP2023093642A/ja active Pending
-
2025
- 2025-01-31 AU AU2025200665A patent/AU2025200665A1/en active Pending
- 2025-07-16 JP JP2025119440A patent/JP2025142045A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2019533675A5 (enExample) | ||
| JP2025065142A5 (enExample) | ||
| CA2970800C (en) | Monomeric fc domains | |
| Holliger et al. | Engineered antibody fragments and the rise of single domains | |
| JP2020530989A5 (enExample) | ||
| Cuesta et al. | Multivalent antibodies: when design surpasses evolution | |
| JP2015513920A5 (enExample) | ||
| JP2024023228A5 (enExample) | ||
| RU2019105693A (ru) | Лечение рака с применением химерного антигенного рецептора в комбинации с ингибитором молекулы, способствующей фенотипу m2 макрофага | |
| IL262321B1 (en) | Compositions and methods for selective protein expression | |
| JP7590034B2 (ja) | Ｎｋｇ２ａを標的にする抗体及びその使用 | |
| FI4063397T3 (fi) | Yksidomeenivasta-aineisiin perustuvia antigeenireseptoreita ja menetelmiä niiden käyttämiseksi | |
| CA2990511A1 (en) | Multispecific antigen binding proteins | |
| JP2018525033A5 (enExample) | ||
| JP2017529067A (ja) | Ｃｄ３結合ドメイン | |
| CA3146019A1 (en) | Anti-dll3 chimeric antigen receptors and uses thereof | |
| JPWO2019246004A5 (enExample) | ||
| JP2018537076A5 (enExample) | ||
| JP2019512207A5 (enExample) | ||
| CA3079363A1 (en) | Multispecific antigen binding proteins | |
| US20180028631A1 (en) | Anti-ssea4 chimeric antigen receptors and their use for treating cancer | |
| CN115066274A (zh) | 三价结合分子 | |
| Hangiu et al. | Tumor targeted 4-1BB agonist antibody-albumin fusions with high affinity to FcRn induce anti-tumor immunity without toxicity | |
| CN114437214B (zh) | 靶向lir1的抗体及其用途 | |
| JPWO2019245991A5 (enExample) |